Premium
Tumor markers of pancreatic carcinoma
Author(s) -
Klavins J. V.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810315)47:6+<1597::aid-cncr2820471423>3.0.co;2-y
Subject(s) - carcinoembryonic antigen , antiserum , heterologous , pancreas , oncofetal antigen , antigen , medicine , pancreatic cancer , carcinoma , pathology , ca19 9 , serial dilution , pancreatic carcinoma , cancer , biology , immunology , biochemistry , immunotherapy , alternative medicine , tumor associated antigen , gene
There is no well‐defined specific tumor marker for carcinoma of the pancreas. Carcinoembryonic antigen (CEA) and alphafetal protein (AFP) are produced by some pancreatic cancer cells. A pancreatic oncofetal antigen (POA) cross‐reacts with other malignant neoplasms and is not produced by all pancreatic carcinomas. An ammonium sulfate fraction (0–25%) from an aqueous extract of pancreatic carcinoma tissues contains an antigen cross‐reacting with extracts of other pancreatic carcinomas and various carcinomas representing all three germinal layers. A heterologous antiserum to this antigen cross‐reacts with sera from patients with pancreatic carcinomas in a dilution of 1:16,000. At lower dilutions this antiserum reacts with sera from patients with other carcinomas and with sera from some apparently healthy individuals.